European Union pom zoo thawj cov tshuaj tiv thaiv COVID-19
European Union pom zoo thawj cov tshuaj tiv thaiv COVID-19

The European Medicines Agency (EMA) has announced that it has issued the conditional authorization (CMA) for Pfizer’s oral coronavirus treatment, Paxlovid.

Amid kev kis tus kab mob tsis tu ncua omicron zog in Teb chaws Europe, EMA tau hais tias thawj cov tshuaj kho mob coronavirus tau raug pom zoo "rau kev kho COVID-19 rau cov neeg laus uas tsis xav tau cov pa ntxiv thiab cov uas muaj feem yuav kis tus kab mob hnyav."

CMA mechanism, EMA tau hais tias, yog siv los ua kom cov txheej txheem tso cai ntawm cov tshuaj "thaum muaj xwm txheej ceev rau pej xeem kev noj qab haus huv."

Nrog rau European regulator qhov kev pom zoo, Paxlovid tau dhau los ua thawj cov tshuaj tiv thaiv kab mob uas tau muab los ntawm qhov ncauj uas tau pom zoo nyob rau hauv EU los kho COVID-19.

Qhov kev pom zoo ntawm Paxlovid follows the authorization in December of antibody treatment Xevudy, produced by GlaxoSmithKline and Vir Biotechnology, as well as Kineret by Swedish Sobi, which was originally an arthritis drug but is able to “reduce” COVID-related inflammation.

Paxlovid tus neeg sib tw, Merck's Lagevrio (molnupiravir), tseem nyob rau hauv kev txiav txim siab los ntawm EMA, vim nws cov txiaj ntsig tau ua pov thawj qis dua li qhov xav tau.

Paxlovid thiab molnupiravir tau txais kev pom zoo los ntawm US Food and Drug Administration nyob rau lub Kaum Ob Hlis xyoo tas los.

 

Print Friendly, PDF & Email

Xov Xwm Lwm Yam